Citadel Advisors
NXTC icon

Citadel Advisors’s NextCure NXTC Stock Holding History

Citadel Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-142
Closed -$817 – 14295
2025
Q1 		$817 Buy
+142
New +$1.25K ﹤0.01% 14211
2024
Q3 		– Sell
-117
Closed -$2.23K – 14926
2024
Q2 		$2.23K Buy
+117
New +$2.27K ﹤0.01% 13719
2024
Q1 		– Sell
-17
Closed -$228 – 15216
2023
Q4 		$228 Sell
17
-108
-86% -$1.56K ﹤0.01% 14084
2023
Q3 		$1.94K Hold
125
– – ﹤0.01% 13784
2023
Q2 		$2.7K Sell
125
-3,992
-97% -$78.6K ﹤0.01% 13757
2023
Q1 		$73.1K Sell
4,117
-1,000
-20% -$19.3K ﹤0.01% 11674
2022
Q4 		$86.6K Buy
5,117
+3,200
+167% +$73.6K ﹤0.01% 11419
2022
Q3 		$63K Sell
1,917
-1,875
-49% -$95.6K ﹤0.01% 11463
2022
Q2 		$214K Buy
+3,792
New +$198K ﹤0.01% 10559
2021
Q2 		– Sell
-875
Closed -$105K – 14178
2021
Q1 		$105K Buy
+875
New +$127K ﹤0.01% 12432
2020
Q4 		– Sell
-1,917
Closed -$202K – 11335
2020
Q3 		$202K Buy
1,917
+667
+53% +$82K ﹤0.01% 8783
2020
Q2 		$322K Buy
+1,250
New +$476K ﹤0.01% 7802
2020
Q1 		– Sell
-650
Closed -$439K – 9987
2019
Q4 		$439K Buy
+650
New +$326K ﹤0.01% 7015

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Citadel Advisors's NXTC Position: Q1 2026 in Review

Citadel Advisors opened a new position in NextCure (NXTC) in Q1 2026: 15,292 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #11623 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NXTC as recently as Q2 2025.

Citadel Advisors first reported a position in NXTC in Q2 2019 and has held it in 26 quarters since. The position peaked at $44.9M in Q4 2019. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Citadel Advisors held 15,292 shares of NextCure worth $161K as of Q1 2026.
  • NextCure was a new Citadel Advisors position in Q1 2026.
  • NextCure made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11623 holding.
  • Citadel Advisors first reported a position in NextCure in Q2 2019 and has held it in 26 quarters since.
  • Citadel Advisors's NextCure position peaked at $44.9M in Q4 2019.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.